Systematic review of genetic association studies involving histologically confirmed non-Alcoholic fatty liver disease

BMJ Open Gastroenterology

Volumn 2, Issue 1, 2015, Pages

  Wood, Kayleigh L ^a   Miller, Michael H ^a   Dillon, John F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; ADIPONECTIN; ANGIOTENSIN II; CANNABINOID RECEPTOR; CHOLESTEROL; FATTY ACID BINDING PROTEIN 2; FATTY ACID TRANSPORTER; GLUCOKINASE; GLUCOSE; GLUTAMATE CYSTEINE LIGASE; INSULIN RECEPTOR; INTERLEUKIN DERIVATIVE; IRON; KRUPPEL LIKE FACTOR 6; LEPTIN RECEPTOR; LIPID; LIPOPROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; RESERPINE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR CLOCK; TUMOR NECROSIS FACTOR; UNCOUPLING PROTEIN 3;

CHOLESTEROL SYNTHESIS; GENE; GENETIC ASSOCIATION STUDY; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HORMONE METABOLISM; HUMAN; INFLAMMATION; LIPID METABOLISM; MEDLINE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TRANSPORT; REVIEW; SCOPUS; SYSTEMATIC REVIEW;

EID: 84949874416     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2014-000019     Document Type: Review

References (100)

1. La Brecque D, Abbas Z, Anania F, et al. World Gastroenterology Organisation Global Guidelines. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Millwaukee, WI: World Gastroenterology Organisation, 2012.
2. British Society of Gastroenterology. Clinical. Commissioning Report. Chronic management. NASH and non-Alcoholic fatty liver disease. Secondary Clinical. Commissioning Report. Chronic management. NASH and non-Alcoholic fatty liver disease c2009. http://www.bsg.org.uk/clinical/commissioning-report/nash-And-nonalcoholic-fatty-liver-disease.html.
3. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
4. Moher D, Liberati A, Tetzlaff J, et al.; The PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med 2009;6: E1000097.
5. Musso G, Gambino R, De Michieli F, et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 2008;47:1167-77.
6. Chen Q-R, Braun R, Hu Y, et al. Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS ONE 2013;8:e65982.
7. de Alwis N, Aithal G, Bugianesi E, et al. Mitochondrial DNA does not contribute to the heritability of non-Alcoholic fatty liver disease. Mitochondrion 2011;11:234-5.
8. Gerhard GS, Chu X, Wood GC, et al. Next-generation sequence analysis of genes associated with obesity and nonalcoholic fatty liver disease-related cirrhosis in extreme obesity. Hum Hered 2013;75:144-51.
9. GeneCards Human Gene Database. Secondary GeneCards Human Gene Database c2014. http://www.genecards.org.
10. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
11. Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-Alcoholic fatty liver disease in Japanese. PLoS ONE 2012;7(6):e38322.
12. Sookoian S, Castaño GO, Burgueño AL, et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-16.
13. Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010;11:172-2.
14. Zain SM, Mohamed R, Mahadeva S, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-Alcoholic fatty liver disease. Hum Genet 2012;131:1145-52.
15. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17.
16. Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52: 1274-80.
17. Verrijken A, Beckers S, Francque S, et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity 2013;21:2138-45.
18. Guichelaar MMJ, Gawrieh S, Olivier M, et al. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity 2013;21:1935-41.
19. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
20. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904- 12.
21. Petta S, Grimaudo S, Cammà C, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-Alcoholic fatty liver disease. J Hepatol 2012;56:1356-62.
22. Corbin KD, Abdelmalek MF, Spencer MD, et al. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J 2013;27:1674-89.
23. Gorden A, Yang R, Yerges-Armstrong LM, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-Alcoholic fatty liver disease in morbid obesity. Hum Hered 2013;75:34-43.
24. Sookoian S, Pirola CJ. Meta-Analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
25. Valenti L, Motta BM, Alisi A, et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2012;54:588-93.
26. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4.
27. Gawrieh S, Marion MC, Komorowski R, et al. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci 2012;57:952-7.
28. Rey J-W, Noetel A, Hardt A, et al. Pro12Ala polymorphism of the peroxisome proliferator-Activated receptor γ2 in patients with fatty liver diseases. World J Gastroenterol 2010;16:5830-7.
29. Dongiovanni P, Rametta R, Fracanzani AL, et al. Lack of association between peroxisome proliferator-Activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-Alcoholic fatty liver disease: A case control study. BMC Gastroenterology 2010;10:102-8.
30. Domenici FA, Brochado MJF, Martinelli Ade LC, et al. Peroxisome proliferator-Activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: A study in Brazilian patients. Gene 2013;529:326-31.
31. Yoneda M, Hotta K, Nozaki Y, et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2008;8:27.
32. Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-Analysis. DNA Cell Biol 2013;32:188-98.
33. Valenti L, Nobili V, Al-Serri A, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011;55:1409-14.
34. Sazci A, Akpinar G, Aygun C, et al. Association of apolipoprotein E polymorphisms in patients with non-Alcoholic steatohepatitis. Dig Dis Sci 2008;53:3218-24.
35. De Feo E, Cefalo C, Arzani D, et al. A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Mol Biol Rep 2012;39:7381-8.
36. Gambino R, Cassader M, Pagano G, et al. Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 2007;45:1097-107.
37. Musso G, Cassader M, De Michieli F, et al. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011;94:1033-42.
38. Dong H, Wang J, Li C, et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 2007;46:915-20.
39. Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-Alcoholic steatohepatitis. J Hepatol 2004;40:781-6.
40. Carulli L, Canedi I, Rondinella S, et al. Genetic polymorphisms in non-Alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-Alcoholic steatohepatitis. Dig Liver Dis 2009;41:823-8.
41. Oliveira CPMS, Stefano JT, Cavaleiro AM, et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-Alcoholic fatty liver disease. J Gastroenterol Hepatol 2010;25:357-61.
42. El-Koofy NM, El-Karaksy HM, Mandour IM, et al. Genetic polymorphisms in non-Alcoholic fatty liver disease in obese Egyptian children. Saudi J Gastroenterol 2011;17:265-70.
43. Musso G, Bo S, Cassader M, et al. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr 2013;98:895-906.
44. Musso G, Cassader M, Bo S, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1109-20.
45. Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. J Hepatol 2012;56:448-54.
46. Aller R, De Luis DA, Izaola O, et al. Role of -55CT polymorphism of UCP3 gene on non alcoholic fatty liver disease and insulin resistance in patients with obesity. Nutr Hosp 2010;25:572-6.
47. Lu SC. Glutathione synthesis. Biochim Biophys Acta 2013;1830: 3143-53.
48. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-80.
49. Yang HR, Ko JS, Seo JK. Role of tumor necrosis factor-α promoter polymorphism and insulin resistance in the development of non-Alcoholic fatty liver disease in obese children. Paediatr Gastroenterol Hepatol Nutr 2012;15:44-51.
50. Hu Z-W, Luo H-B, Xu Y-M, et al. Tumor necrosis factor-Alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg 2009;72:215-21.
51. Chowdhury SD, Ramakrishna B, Eapen CE, et al. Fibrosis in non-Alcoholic fatty liver disease: correlation with simple blood indices and association with tumor necrosis factor-Alpha polymorphisms. Trop Gastroenterol 2013;34:31-5.
52. Aller R, de Luis DA, Izaola O, et al. G308A polymorphism of TNF-Alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients. Ann Hepatol 2010;9:439-44.
53. Tokushige K, Takakura M, Tsuchiya-Matsushita N, et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007;46:1104-10.
54. Wong VW-S, Wong GL-H, Tsang SW-C, et al. Genetic polymorphisms of adiponectin and tumor necrosis factor-Alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol 2008;23:914-21.
55. Nozaki Y, Saibara T, Nemoto Y, et al. Polymorphisms of interleukin-1 beta and beta 3-Adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2004;28(8 Suppl Proceedings):106S-110S.
56. Akyildiz M, Gunsar F, Nart D, et al. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:192-8.
57. Brun P, Castagliuolo I, Floreani AR, et al. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Gut 2006;55:1212.
58. Tokushige K, Hashimoto E, Noto H, et al. Influence of adiponectin gene polymorphisms in Japanese patients with non-Alcoholic fatty liver disease. J Gastroenterol 2009;44:976-82.
59. Gupta AC, Misra R, Sakhuja P, et al. Association of adiponectin gene functional polymorphisms (-11377C/G and +45T/G) with nonalcoholic fatty liver disease. Gene 2012;496:63-7.
60. Zain SM, Mohamed Z, Mahadeva S, et al. Impact of leptin receptor gene variants on risk of non-Alcoholic fatty liver disease and its interaction with adiponutrin gene. J Gastroenterol Hepatol 2013;28:873-9.
61. Aller R, De Luis DA, Izaola O, et al. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. Eur Rev Med Pharmacol 2012;16:335-41.
62. Swellam M, Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. IUBMB Life 2012;64:180-6.
63. Sookoian S, Castaño G, Gianotti TF, et al. Genetic variants in STAT3 are associated with nonalcoholic fatty liver disease. Cytokine 2008;44:201-6.
64. Sookoian S, Castaño G, Gemma C, et al. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol 2007;13:4242-8.
65. Sazci A, Ergul E, Aygun C, et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem Funct 2008;26:291-6.
66. Serin E, Güçlü M, Ataç FB, et al. Methylenetetrahydrofolate reductase C677T mutation and nonalcoholic fatty liver disease. Dig Dis Sci 2007;52:1183-6.
67. Assy N, Bekirov I, Mejritsky Y, et al. Association between thrombotic risk factors and extent of fibrosis in patients with non-Alcoholic fatty liver diseases. World J Gastroenterol 2005;11:5834-9.
68. Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008;135:282-91.1.
69. Valenti L, Dongiovanni P, Fracanzani AL, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003;35:172-8.
70. Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010;138:905- 12.
71. Deguti MM, Sipahi AM, Gayotto LCC, et al. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz J Med Biol Res 2003;36:739-45.
72. Zamin I, Mattos AA, Mattos AZ, et al. Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis. Arq Gastroenterol 2006;43:224-8.
73. Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, et al. Nonalcoholic fatty liver disease and HFE gene mutations: A Polish study. World J Gastroenterol 2010;16:2531-6.
74. Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 2012;56: 1730-40.
75. Valenti L, Rametta R, Dongiovanni P, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS ONE 2012;7:e48804-.
76. Zain SM, Mohamed Z, Mahadeva S, et al. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-Alcoholic fatty liver disease in a multi-ethnic population. PLoS ONE 2013;8:e58538.
77. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39:967-71.
78. Yoneda M, Hotta K, Nozaki Y, et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009;29:1078-85.
79. Espino A, Villagrán A, Vollrath V, et al. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-Alcoholic fatty liver disease. Ann Hepatol 2011;10:493-501.
80. Dongiovanni P, Valenti L, Rametta R, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-Alcoholic fatty liver disease. Gut 2010;59:267-73.
81. Tan HL, Zain SM, Mohamed R, et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-Alcoholic fatty liver disease: An interaction study with adiponutrin gene. J Gastroenterol 2014;49:1056-64.
82. Musso G, Gambino R, Pacini G, et al. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009;49:426-35.
83. Aller R, de Luis DA, Pacheco D, et al. Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease. Nutr Hosp 2012;27:1637-42.
84. Rossi F, Bellini G, Alisi A, et al. Cannabinoid receptor type 2 functional variant influences liver damage in children with non-Alcoholic fatty liver disease. PLoS ONE 2012;7:e42259.
85. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-Alcoholic fatty liver disease. Nat Commun 2014;5:4309.
86. Dongiovanni P, Petta S, Maglio C, et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-14.
87. Sookoian S, Castano GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61:515-25.
88. Oruc N, Ozutemiz O, Berdeli A, et al. Common SPINK-1 mutations do not predispose to the development of non-Alcoholic fatty liver disease. Ann Hepatol 2009;8:116-19.
89. Iwata R, Baur K, Stieger B, et al. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-Alcoholic fatty liver disease. Clin Sci 2011;120:287-96.
90. Varela NM, Quiñones LA, Orellana M, et al. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women. Biol Res 2008;41:81-92.
91. Sookoian S, Castaño GO, Burgueño AL, et al. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 2010;20:1-8.
92. Auinger A, Valenti L, Pfeuffer M, et al. A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. Horm Metab Res 2010;42:854-9.
93. Aller R, De Luis DA, Fernandez L, et al. Influence of Ala54Thr polymorphism of fatty acid-binding protein 2 on histological alterations and insulin resistance of non alcoholic fatty liver disease. Eur Rev Med Pharmacol 2009;13:357-64.
94. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010;139:1567.
95. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
96. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-19.
97. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
98. Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013;132:783-92.
99. Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, et al. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. Hepatology 2013;57:505-14.
100. Howlett DC, Drinkwater KJ, Lawrence D, et al. Findings of the UK national audit evaluating image-guided or image-Assisted liver biopsy. Part II. Minor and major complications and procedure-related mortality. Radiology 2013;266:226-35.